—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

Men treated with androgen deprivation therapy (ADT) for prostate cancer had a significantly higher risk of dementia and other neurocognitive disorders, according to a meta-analysis of more than 2.5 ...

The ARASEC study prospectively examined darolutamide plus ADT in US men with mHSPC, but used a historical control group receiving ADT monotherapy from the phase 3 CHAARTED trial for matching and ...

U.S. study supports findings from a global trial using an external control arm ...

An analysis of four randomized controlled studies in patients with advanced prostate cancer who had received early vs. deferred ADT as primary therapy showed that early androgen suppression ...

I f prostate cancer has spread to other areas of your body, your doctor may recommend androgen deprivation therapy (ADT), which halts the production of androgen hormones, especially testosterone.

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer. The combination of Nubeqa (darolutamide) ...

Metastatic prostate cancer is cancer that began in the prostate but has spread to other parts of the body. There's no cure, but there are a number of effective treatments you can discuss with a ...

Patients with high-risk prostate cancer who had a higher dose of radiation plus long-term androgen deprivation therapy tended to live longer than those who had a lower dose. A higher dose of radiation ...

JCO Precision Oncology Conversations podcasts feature discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations ...

Recently, the research group led by Dr. Dechao Feng, Lecturer at University College London (UCL) and Distinguished Research ...